The dermatology biosimilar market is projected to grow from USD 24.7 billion in 2025 to USD 42.6 billion by 2035, at a CAGR of 5.6%. Adalimumab Biosimilars will dominate with a 48.3% market share, while plaque psoriasis will lead the indication segment with a 55.7% share.